The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims to determine if PA would change the course of the orbitopathy in TED patients by altering the progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease and elevated intraocular pressure will be randomised to the PA treatment and the other eye will serve as a control eye and will be treated with Timolol.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Timolol
- drug : Prostaglandin Analog
Phase: Phase 4
Ages Eligible For Study:
- mild or moderate to severe thyroid eye disease in one or both eyes - age > 18 years - informed consent - intraocular pressure > 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or both eyes - not on current prostaglandin analog intraocular pressure lowering therapy